Buy Stock In Gw Pharmaceuticals [HOT]
Under the terms of the agreement, holders of GW ADSs, which each represent 12 GW ordinary shares, will be entitled to receive $220.00 for each GW ADS, of which $200.00 will be paid in cash and $20.00 in Jazz ordinary shares. This represents a premium of approximately 50 percent over GW's closing stock price on February 2, 2021, of $146.25 and 60 percent over GW's 30-day volume weighted average price of $137.17.
buy stock in gw pharmaceuticals
The two companies will host a conference call today at 8:30 AM ET to discuss this transaction. The live webcast may be accessed from the Investors section of the companies' websites at www.jazzpharmaceuticals.com and www.gwpharm.com. Please connect prior to the start of the conference call to ensure adequate time for any software downloads that may be necessary. Investors may participate in the conference call by dialing (855) 353-7924 in the U.S., or (503) 343-6056 outside the U.S., and entering passcode 5591214.
A replay of the conference call will be available through February 10, 2021, by dialing (855) 859-2056 in the U.S., or (404) 537-3406 outside the U.S., and entering passcode 5591214. An archived version of the webcast will be available for at least one week in the Investors section of the companies' websites at www.jazzpharmaceuticals.com or www.gwpharm.com.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Valuing GW Pharmaceuticals stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of GW Pharmaceuticals's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
The Barchart Technical Opinion widget shows you today's overally Barchart Opinion with general information on how to interpret the short and longer term signals. Unique to Barchart.com, Opinions analyzes a stock or commodity using 13 popular analytics in short-, medium- and long-term periods. Results are interpreted as buy, sell or hold signals, each with numeric ratings and summarized with an overall percentage buy or sell rating. After each calculation the program assigns a Buy, Sell, or Hold value with the study, depending on where the price lies in reference to the common interpretation of the study. For example, a price above its moving average is generally considered an upward trend or a buy.
Two years ago, I highlighted the very first company to have an FDA approved cannabis product. GW Pharmaceuticals (NASDAQ:GWPH) had just gained approval for their epilepsy drug. There was momentum with their drug being accepted by insurers and Medicaid as well as patients that needed them. Since then, several more states have changed their status with regards to accepting cannabis-derived medicine via Medicaid. Revenues have grown steadily over the past quarters. Earnings per share are still negative, though. But the company has just posted above-expectations revenues and earnings and has guided that they see continued growth with their product. As well, they continue to invest in their future with a strong pipeline of drugs. With this success, perhaps, finally, GW Pharmaceuticals stock will begin to move higher over a longer period of time.
I did an analysis of this company about 2 solid years ago where I thought that GWPH was a buy. Every stock is a buy. But that does not mean you will be profitable after having done so. GWPH is one of those stocks. This was the heyday of the cannabis industry where a lot of money was pouring into a new, fledgling industry. Canadian cannabis had just been legalized and a whole lot of companies started producing a whole lot of cannabis. But Canadian dispensaries were slow to roll out and these various companies ended up holding a lot of excess inventory.
Wall Street didn't see the deal coming. Jazz focuses on sleeping disorders. But the deal places a wealthy premium on GWPH stock and diminishes the likelihood of other bidders, Needham analyst Serge Belanger said in a report to clients.
Under the terms of the deal, Jazz will pay $220 per American depositary share. That's split in $200 per ADS in cash and $20 in Jazz ordinary shares. The entire deal values GWPH stock at $7.2 billion, or $6.7 billion net of GW Pharma's cash.
In addition to Epidiolex, Jazz will add a growing pipeline of cannabis-based drugs. Investors in GWPH stock are watching nabiximols, a potential treatment for spasticity-related conditions. The company expects to have study results beginning in mid-2021.
The deal also sent shares of fellow epilepsy-focused biotech companies flying. Zogenix (ZGNX) stock roared up 9.5% to 21.55. Xenon Pharmaceuticals (XENE) popped 5.4% to 17.16. Zynerba Pharmaceuticals (ZYNE) surged 27.4% to 4.53.
Alger Spectra Fund recently released its Q3 2020 Investor Letter, a copy of which you can download here. Class A shares of the Alger Spectra Fund outperformed the Russell 3000 Growth Index during the third quarter of 2020. You should check out Alger Spectra Fund's top 5 stock picks for investors to buy right now, which could be the biggest winners of 2021.
In the Q3 2020 Investor Letter, Alger Spectra Fund Fund highlighted a few stocks and GW Pharmaceuticals Plc (NASDAQ:GWPH) is one of them. GW Pharmaceuticals Plc (NASDAQ:GWPH) is a pharmaceutical company. Year-to-date, GW Pharmaceuticals Plc (NASDAQ:GWPH) stock gained 9.9% and on December 29th it had a closing price of $114.91. Here is what Alger Spectra Fund said:
"GW Pharmaceuticals is producing cannabinoid-based pharmaceuticals without tetrahydrocannabinol, or THC, which is a mood-altering component in marijuana. These cannabinoids enable the identification of unique chemotypes that have positive effects on different diseases, including epilepsy, inflammatory disorders and psychosis. GW's near-term focus is developing Epidiolex for use with treatment resistant epilepsy. with up to 40 Vo of epileptic patients continuing to have seizures after using three or more different drugs. The sales growth of Epidiolex has been disappointing because the virtual nature of diagnosis and prescribing drugs during the Covid-19 pandemic is challenging the adoption of this newer type of therapy; shares of GW Pharmaceuticals thus underperformed during the third quarter."
In Q3 2020, the number of bullish hedge fund positions on GW Pharmaceuticals Plc (NASDAQ:GWPH) stock decreased by about 6% from the previous quarter (see the chart here), so a number of other hedge fund managers don't believe in GWPH's growth potential. Our calculations showed that GW Pharmaceuticals Plc (NASDAQ:GWPH) isn't ranked among the 30 most popular stocks among hedge funds.
The top 10 stocks among hedge funds returned 216% since the end of 2014 and outperformed the S&P 500 Index ETFs by more than 121 percentage points. We know it sounds unbelievable. You have been dismissing our articles about top hedge fund stocks mostly because you were fed biased information by other media outlets about hedge funds' poor performance. You could have doubled the size of your nest egg by investing in the top hedge fund stocks instead of dumb S&P 500 ETFs. Below you can watch our video about the top 5 hedge fund stocks right now. All of these stocks had positive returns in 2020.
At Insider Monkey we scour multiple sources to uncover the next great investment idea. For example, Federal Reserve has been creating trillions of dollars electronically to keep the interest rates near zero. We believe this will lead to inflation and boost real estate prices. So, we recommended this real estate stock to our monthly premium newsletter subscribers. We go through lists like the 10 most profitable companies in the world to pick the best large-cap stocks to buy. Even though we recommend positions in only a tiny fraction of the companies we analyze, we check out as many stocks as we can. We read hedge fund investor letters and listen to stock pitches at hedge fund conferences. You can subscribe to our free daily newsletter on our website:
Shares in GW Pharma quickly rose to match the price promised in the deal, while Jazz stock traded flat. Shares in Zogenix, a biotech developing a competing treatment to Epidiolex for Dravet syndrome, rose by nearly 10%.
As part of the deal, Jazz will snap up GW (GWPH) for $220 per ADS (American Depository Share), which consists of $200 in cash and $20 in Jazz stock per share. GW shares closed 45% higher on Feb. 3, while Jazz fell 3.9%.
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.
American Green (ERBB). CannaGrow Holdings (CGRW). Hemp (HEMP). Medical Marijuana (MJNA). WeedHire International (WDHR). (Amusingly, the stock with the ticker symbol is THC is not a pot firm but giant hospital owner Tenet (THC).)
But once you weed (sorry, again) out the large number of speculative penny stocks that don't trade on big exchanges like the NYSE or Nasdaq, you are left with just a handful of companies that seem legit.
The company is working on several cannabis-based drugs. The stock popped more than 25% this week after the American Academy of Neurology reported there were some promising results for patients in a clinical trial taking GW Pharmaceuticals' Epidiolex drug to treat epileptic seizures. 041b061a72